TY - JOUR
T1 - Case Report
T2 - First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
AU - Kjær, Lasse
AU - Skov, Vibe
AU - Larsen, Morten Kranker
AU - Boklund, Tobias Idor
AU - Andersen, Morten
AU - Kefala, Maria
AU - Knudsen, Trine A
AU - Schjellerup Eickhardt-Dalbøge, Christina
AU - Stiehl, Thomas
AU - Gudmand-Høyer, Johanne
AU - Snyder, Jordan
AU - Holmström, Morten
AU - Andersen, Mads H
AU - Ottesen, Johnny T
AU - Ellervik, Christina
AU - Hasselbalch, Hans C
N1 - Copyright © 2023 Kjær, Skov, Larsen, Boklund, Andersen, Kefala, Knudsen, Schjellerup Eickhardt-Dalbøge, Stiehl, Gudmand-Høyer, Snyder, Holmström, Andersen, Ottesen, Ellervik and Hasselbalch.
PY - 2023
Y1 - 2023
N2 - Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated individual during a 12 year follow-up from initial identification of CALR clonal hematopoiesis of indeterminate potential (CHIP) to the diagnosis of pre-MF. The pre-diagnostic exponential development dynamics of the malignant clone demonstrated close correlation with the platelet counts, neutrophil-to-lymphocyte (NLR) ratio, and inversely correlated to hemoglobin and erythrocyte counts. Backward extrapolation of the growth rate indicated the potential for discovery of the malignant clone many years prior to presentation of overt disease, opening a window of opportunity for early treatment intervention. We did not find any additional mutations associated with MPNs and the current case report provides novel information regarding the development of a driver mutation and the association with blood cell counts prior to clinical manifestation of symptoms suggesting that pre-diagnostic dynamics may supplement future diagnostic criteria for early diagnosis and intervention in MPN patients.
AB - Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated individual during a 12 year follow-up from initial identification of CALR clonal hematopoiesis of indeterminate potential (CHIP) to the diagnosis of pre-MF. The pre-diagnostic exponential development dynamics of the malignant clone demonstrated close correlation with the platelet counts, neutrophil-to-lymphocyte (NLR) ratio, and inversely correlated to hemoglobin and erythrocyte counts. Backward extrapolation of the growth rate indicated the potential for discovery of the malignant clone many years prior to presentation of overt disease, opening a window of opportunity for early treatment intervention. We did not find any additional mutations associated with MPNs and the current case report provides novel information regarding the development of a driver mutation and the association with blood cell counts prior to clinical manifestation of symptoms suggesting that pre-diagnostic dynamics may supplement future diagnostic criteria for early diagnosis and intervention in MPN patients.
UR - http://www.scopus.com/inward/record.url?scp=85159894770&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1176173
DO - 10.3389/fonc.2023.1176173
M3 - Journal article
C2 - 37223675
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1176173
ER -